Episode Details

How safe are MS therapies? And how do we actually know?

In this episode, neurologist Dr. Nora Möhn explains the concept of pharmacovigilance — the continuous monitoring of drug safety from early development through approval and real-world use.

This conversation was originally published in September 2023 on the German MS-Perspektive podcast. For this English edition, regulatory references and country-specific details have been carefully adapted to reflect internationally relevant systems and resources. The medical content remains fully up to date.

You will learn:

• What pharmacovigilance means and why it is essential for people with MS

• How safety data is collected in Phase I–IV clinical trials

• How rare side effects are detected after market approval

• How neurologists assess the benefit-risk profile of MS therapies

• What special considerations apply during pregnancy, in children/adolescents, and in older patients

• How patients can report suspected side effects in different countries

• Why ongoing monitoring builds trust and treatment confidence

A well-monitored therapy not only slows down MS — it enables long-term safety, confidence, and self-determined living.

🔗 Read the full article here: https://ms-perspektive.de//en/154-pharmacovigilance

If you would like to report suspected side effects, you can contact your national medicines authority. Here are official resources:

European Union European Medicines Agency (EMA) – EudraVigilance https://www.adrreports.eu https://www.ema.europa.eu

United States FDA MedWatch Program https://www.fda.gov/medwatch https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

United Kingdom MHRA Yellow Card Scheme https://yellowcard.mhra.gov.uk

Canada Health Canada – Canada Vigilance Program https://www.canada.ca/en/health